Bristol Myers Squibb and Samsung Biologics have an existing manufacturing agreement for a commercial antibody cancer drug and have expanded the strategic r...
Located in Sapporo, Japan, Hokkaido University Hospital stands as one of the most prominent medical institutions in the country. Affiliated with Hokkaido U...
The primary objective is to evaluate VISTA as a biomarker to guide patient selection and treatment optimization for VISTA-targeted therapies where no stand...
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, announced a new study as part of the I-SPY 2 trial, sponsored and operated by ...
Genetic Technologies Limited (GTG), a pioneering global leader in genomics-based tests focused on health, wellness, and the battle against serious diseases...
SomaLogic’s SomaScan® platform was used to target 15 markers shared among all cancer types. In a new paper published in Nature's Scientific Repo...
– Results Show Encouraging Activity of Trodelvy in Combination with KEYTRUDA in 1L Metastatic NSCLC Across all PD-L1 Subgroups and Histologies Studie...
US-based startup Zenas BioPharma has entered into a license and collaboration agreement with Bristol Myers Squibb Company to develop and commercialise ob...
Over the past few years, exosomes have gained significant attentions as a promising drug delivery vehicle in both academic and biomedical industry circles....
“We are building a new ecosystem in global public health,” said Anuradha Gupta, President of Global Immunization at Sabin. “We aim to cre...
Designations for Daiichi Sankyo and AstraZeneca's ENHERTU include patients with HER2 expressing metastatic solid tumors and HER2 positive metastatic colo...
OMTX705 is a novel antibody–drug conjugate (ADC) molecule targeting fibroblast-activating protein α (FAPα). FAPα is a dimeric type ...
ImmunoGen to Receive $34 Million1 in Upfront and Near-Term Milestone Payments and is Eligible to Receive Potential Regulatory and Commercial Milestone Paym...
These models are essential for testing in vivo efficacy of novel therapeutics against lung cancer, elevating the prospects for significant advances in the ...
© 2024 Biopharma Boardroom. All Rights Reserved.
